The use of bucillamine in the treatment of gout
AssigneeRevive Therapeutics Ltd
InventorMichael L. Selley
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising, bucillamine, including bucillamine and allopurinol or colchicine, or pharmaceutically acceptable salts or solvates thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients. Methods for use of the said compositions in the treatment of gout and metabolic syndrome are also disclosed.
Claims29
A pharmaceutical composition comprising bucillamine or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients, for use in the treatment or prevention of gout, and/or the attenuation of metabolic syndrome.
(canceled)
(canceled)
A method for the treatment or prevention of gout, and/or the attenuation of metabolic syndrome in a mammal comprising administering a therapeutically effective amount of bucillamine or a pharmaceutically acceptable salt or solvate thereof to a mammal in need thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-34. (canceled)
(canceled)
Dependencies are inferred from the claim text.